Last reviewed · How we verify

Lenvatinib Pill

Assistance Publique - Hôpitaux de Paris · FDA-approved active Small molecule Quality 5/100

Lenvatinib Pill is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved. Also known as: percutaneous ablative procedure, E7080, Level 0 Lenvatinib, Level -1 Lenvatinib.

At a glance

Generic nameLenvatinib Pill
Also known aspercutaneous ablative procedure, E7080, Level 0 Lenvatinib, Level -1 Lenvatinib, Level -2 Lenvatinib
SponsorAssistance Publique - Hôpitaux de Paris
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lenvatinib Pill

What is Lenvatinib Pill?

Lenvatinib Pill is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.

Who makes Lenvatinib Pill?

Lenvatinib Pill is developed and marketed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

Is Lenvatinib Pill also known as anything else?

Lenvatinib Pill is also known as percutaneous ablative procedure, E7080, Level 0 Lenvatinib, Level -1 Lenvatinib, Level -2 Lenvatinib.

What development phase is Lenvatinib Pill in?

Lenvatinib Pill is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing